Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ProFound Therapeutics and China’s Argo Biopharmaceutical, among others.
Novartis Deals in Cardio Again, Dropping $1.4B To Acquire Tourmaline